Abstract
CHA2DS2-VASc and HAS-BLED scores are widely used for risk stratification to guide decision making in use of anticoagulation therapy in atrial fibrillation (AF). RE-LY trial compared efficacy of dabigatran vs. Warfarin in AF. We evaluated accuracy of CHA2DS2-VASc vs. HAS-BLED in predicting risk of
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
